The Accelerate@Babraham concept complements our ongoing support of the Cambridge life science cluster through the provision of access to the campus community and infrastructure without the need to be an established occupier on site.
Now in it's second year, the Accelerate@Babraham Start-ups Competition goes one step further, giving new companies the chance to win one of five spaces on the Accelerate programme for a five-month period from September 2019.
Up to five competition finalists will win access to Accelerate@Babraham’s bio-incubator facilities, including communal equipped laboratory space, flexible workspace within our stimulating and supportive environment and access to our community hub which includes office, meeting and social spaces. In addition, finalists will receive:
Applications for Accelerate@Babraham’s Start-ups Competition have now closed.
Shortlisted applicants will be notified at the beginning of May and will be invited to pitch at the Babraham Investor Conference on 15th May where a judging panel of business leaders will choose up to five finalists.
The competition is open to early stage start-ups (who are yet to raise their first £1m funding/investment) with a life science sector focus, eg: therapeutics, synthetic biology, life science tools & technologies, diagnostics or any transformative healthcare solutions. Applicants must be a team of at least two members and available to move to Cambridge (UK) for the entire acceleration programme. A passion for life science, healthcare and entrepreneurship is critical!
Olivia joined SV Health Investors in August 2018 as Principal in the Biotechnology team based in London.
David is Chief Scientific Advisor to Medicxi, while creating new biotech companies, together with Richard Mason, at the Foundation Institute for 21st Century Medicine, based at Babraham Research Campus.
Jane Osbourn is VP R&D at AstraZeneca (formerly MedImmune) with in depth experience of biologics drug discovery and development. She is also Chair of the BioIndustry Association (BIA), the UK trade association for innovative biotech companies.
Dr. Vishal Gulati is a venture partner at Draper Esprit a leading European venture capital firm. His investment interests include healthtech, omics and synthetic biology.
Derek is Chief Executive of Babraham Bioscience Technologies, the company which manages and develops the Babraham Research Campus.
John is leader of AstraZeneca’s Partnering and Strategy group, which focuses on business deals ranging from acquisitions and clinical collaborations to licensing agreements and new industry partnerships.
(+44) 1223 496 000
Babraham Bioscience Technologies Ltd
Babraham Research Campus
CB22 3AT, United Kingdom
01223 813 557